ARX
Asset Logo

Aroa Biosurgery Limited

🇦🇺 ASX

🧬 BIOTECHNOLOGY

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

-2.92%
Annual Growth

4 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

13
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. The company develops, manufactures, sells, distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement, and complex wounds.

📈 Performance

Price History

-12.67%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.66

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in ARX

13

📊 Total Capital Earnings

$8K

🔃 Average investment frequency

17 weeks

💵 Average investment amount

$3,900

Last time a customer invested in ARX

12 days
ARX investor breakdown
💵 Income of investors

More than 200k

150k - 200k

12%

100k - 150k

12%

50k - 100k

41%

Less than 50k

29%
👶 Age of investors

18 - 25

26 - 34

31%

35 - 90

69%
🙋 Legal gender of investors

Female

54%

Male

46%

Pearlers who invest in ARX also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

4.35%

📊 Share price

$104.33 AUD

🧱 MATERIALS

⛳️ DIVERSIFIED

💸 FINANCIALS

Find Out More

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

🙌 Performance (5Yr p.a)

82.15%

📊 Share price

$12.36 AUD

📦 LOGISTICS

Paladin Energy Ltd. engages in the development and operation of uranium mines. The company is headquartered in Perth, Western Australia. The firm also owns a portfolio of uranium exploration and development assets in Canada and Australia. Its segments include Exploration, Namibia and Australia. The LHM is located in central western Namibia approximately 80 kilometers (km) east of Swakopmund and 85 km northeast of the Walvis Bay major deepwater harbor. Its exploration projects include Michelin, Manyingee and Mount Isa. The Company, through its subsidiary Aurora Energy Ltd, holds a 100% interest in over 98,320 hectares of mineral exploration licenses. These are located within the Central Mineral Belt of Labrador, Canada. The company has a 100% interest in the Manyingee Project. This project is a sandstone hosted uranium project consisting of 41 Mlb across two deposits. The company wholly-owns a project comprised of three promising uranium exploration sites in Queensland.

🙌 Performance (5Yr p.a)

1951.79%

📊 Share price

$8.20 AUD

⚡️ ENERGY

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The firm is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).

🙌 Performance (5Yr p.a)

229.50%

📊 Share price

$22.58 AUD

🧬 BIOTECHNOLOGY

Johns Lyng Group Ltd. engages in the provision of building and restoration services. The company is headquartered in Melbourne, Victoria and currently employs 2,300 full-time employees. The company went IPO on 2017-10-26. The Company’s core business is built on its ability to rebuild and restore a variety of properties and contents after damage by insurable events, including impact, weather and fire events. The firm operates through four segments: Insurance Building and Restoration Services, Commercial Building Services, Commercial Construction, and Other. Its Insurance Building and Restoration services include 24/7 emergency service, international availability, fire damage, vehicle and structural impact, storm damage and tree removal, mold and biohazard, contents and surface restoration, building maintenance, total claims handling, and hazardous waste removal. Its Commercial Services include project management, warehousing & logistics, reactive maintenance, preventative maintenance, floorcovering, retail shopfitting, and others.

🙌 Performance (5Yr p.a)

22.66%

📊 Share price

$4.26 AUD

👷‍♀️ CONSTRUCTION

📈 HIGH PRICE GROWTH

Want more shares? Try these...

Angel Seafood Holdings Ltd. is an aquaculture company, which engages in the ownership and provision of oyster production licenses and leases. The company is headquartered in Port Lincoln, South Australia. The company went IPO on 2018-02-21. The firm has one operating segment, the multi-bay operations in South Australia that include oyster nursery and grow out operations in Cowell, and conditioning and finishing in Coffin Bay. The firm primarily sells oysters to the domestic market. The firm also runs a multi-bay strategy with nursery and oyster grow out operations in Cowell and Haslam with a holding capacity of over 20 million oysters, and Coffin Bay with a capacity to finish up to 12 million oysters per year. The Company’s subsidiaries include Angel Oysters Australia Pty Ltd and Angel Seafood Infrastructure Pty Ltd.

🙌 Performance (5Yr p.a)

13.85%

📊 Share price

$0.02 AUD

📈 HIGH PRICE GROWTH

🍔 FOOD PRODUCTS

Askari Metals Ltd. Engages in gold and lithium exploration. The company is headquartered in Perth, Western Australia. The company went IPO on 2021-07-07. The company has assembled a portfolio of lithium, copper, gold, uranium, and copper-gold exploration/mineral resource development projects in Western Australia, Northern Territory, New South Wales, southern Tanzania, and Namibia. Its projects include UIS Lithium Project, Yarrie Lithium Project, Hillside Lithium Project, Myrnas Hill Lithium Project, Barrow Creek Lithium Project, Horry Copper Project, Callawa Copper Project, Burracoppin Gold Project, Mt Maguire Gold and Base Metal Project, Springdale Copper-Gold Project, Red Peak Project, and Matemanga Uranium Project. The Uis Lithium Project (EPL 7345 and EPL 8535) covers an area of 308.12 square kilometers within the Erongo Region of west-central Namibia, Africa. The Matemanga Uranium project is in southern Tanzania.

📊 Share price

$0.02 AUD

⛏️ MINING

Artemis Resources Ltd. engages in the exploration and development of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-03-16. The company holds three projects in Western Australia, including Carlow Castle gold-copper-cobalt project in the West Pilbara; Paterson Central project in the Paterson Province (located adjacent to Greatland Gold / Newcrest’s recent gold-copper discovery at Havieron, and Osborne joint venture in the West Pilbara. The Carlow Castle gold-copper-cobalt project is situated in the mining jurisdiction of Western Australia’s West Pilbara, 25 kilometers (km) from the regional city of Karratha. The Carlow deposit is on granted exploration license E47/1797 and is only 35 km from Artemis resources 100% owned Radio Hill Processing Plant. The Lulu Creek Gold Project lies 20 km to the west of Artemis’s Carlow Castle deposit. The Paterson Central Gold-Copper Project is located within the Yaneena Basin of the Paterson Province. The company controls 144 square kilometers (km2) of prospective tenure adjacent to Green Tech and Azure Minerals.

🙌 Performance (5Yr p.a)

-12.14%

📊 Share price

$0.01 AUD

⛏️ MINING

📊 Share price

$0.00 AUD
Compare
Add to watchlist